Get the Stockscreener App
3.31
0.30%
0.01
After Hours:
3.30
-0.01
-0.30%
Neonc Technologies Holdings Inc stock is traded at $3.31, with a volume of 135.21K.
It is up +0.30% in the last 24 hours and down -29.72% over the past month.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
See More
Previous Close:
$3.30
Open:
$3.36
24h Volume:
135.21K
Relative Volume:
0.78
Market Cap:
$95.35M
Revenue:
$40,000
Net Income/Loss:
$-38.64M
P/E Ratio:
-1.7975
EPS:
-1.8414
Net Cash Flow:
$-22.21M
1W Performance:
+1.53%
1M Performance:
-29.72%
6M Performance:
-53.25%
1Y Performance:
-68.08%
1-Day Range:
$3.25
$3.5199
1-Week Range:
$3.125
$3.60
52-Week Range:
$2.955
$12.99
Neonc Technologies Holdings Inc Stock (NTHI) Company Profile
Name
Neonc Technologies Holdings Inc
Sector
Industry
Phone
310 663 7831
Address
23975 PARK SORRENTO, CALABASAS
Compare NTHI vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTHI
Neonc Technologies Holdings Inc
|
3.31 | 95.35M | 40,000 | -38.64M | -22.21M | -1.8414 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neonc Technologies Holdings Inc Stock (NTHI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-19-26 | Initiated | Alliance Global Partners | Buy |
| May-18-26 | Initiated | Maxim Group | Buy |
| Apr-24-26 | Initiated | BTIG Research | Buy |
Neonc Technologies Holdings Inc Stock (NTHI) Latest News
NeOnc Technologies Initiated at Buy by Roth Capital - Moomoo
NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst - manilatimes.net
NeOnc Technologies Holdings Gains Roth Capital Coverage as NEO100 and NEO212 Advance Toward Key Clinical and Regulatory Milestones - Quiver Quantitative
Roth Capital Initiates NeOnc Technologies at Buy - marketscreener.com
NeOnc Technologies stock initiated with buy rating at Roth/MKM - Investing.com
NeOnc Technologies stock initiated with buy rating at Roth/MKM By Investing.com - Investing.com Canada
NeOnc Technologies Holdings, Inc. (NTHI) Stock Price, News, Quote & History - Yahoo! Finance Canada
NeOnc Technologies Reports Encouraging Phase 2a NEO100 Results in IDH1-Mutant High-Grade Glioma - Quiver Quantitative
NeOnc’s Delivery may Finally Change the Equation for Brain Cancer’s Next Frontier - marketscreener.com
Nearly half of patients were progression-free at six months. NeOnc plans FDA talks. - stocktitan.net
[8-K] NEONC TECHNOLOGIES HOLDINGS, INC. Reports Material Event - stocktitan.net
NeOnc Technologies Holdings’ NEO100 Phase 2a Glioma Results Highlight Intranasal Brain Cancer Delivery Approach - Quiver Quantitative
NeOnc Charting New Nasal Route to Treating Brain Cancer - GlobeNewswire
In a 24-patient study, 48.9% were progression-free at six months with a nose-delivered brain cancer treatment. - stocktitan.net
Neonc Technologies CFO sells $16,809 in company stock By Investing.com - Investing.com South Africa
Neonc Technologies CFO sells $16,809 in company stock - Investing.com
NeOnc Technologies (NTHI) CFO sells shares under preset plan - stocktitan.net
NeOnc redeems $6M preferred stock with cash from recent offering - Investing.com Nigeria
NeOnc Technologies Redeems All Series A Preferred Shares, Eliminating Potential Dilution and Advancing CNS Pipeline - Quiver Quantitative
In a brain-cancer trial, 48.9% had no worsening at six months. NeOnc also redeemed $6M in stock. - Stock Titan
NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution - marketscreener.com
A $6 million payment kept NeOnc from issuing new shares - stocktitan.net
NeOnc CEO purchases additional shares following trial results By Investing.com - Investing.com South Africa
NEONC TECHNOLOGIES HOLDINGS (NASDAQ: NTHI) CFO Garnett Keithly Acquires 257 Shares at $3.89 Each - Kalkine Media
NeOnc’s $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA - The Manila Times
NeOnc CEO purchases additional shares following trial results - Investing.com
An experimental brain-cancer treatment reached 48.9% at six months, versus a 20% benchmark - Stock Titan
Press Release: NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results - Moomoo
Neonc technologies CEO Thomas Chen buys $39,999 in stock By Investing.com - Investing.com South Africa
Neonc CFO Keithly Garnett buys $1,000 in company stock By Investing.com - Investing.com Nigeria
Neonc technologies CEO Thomas Chen buys $39,999 in stock - Investing.com
Neonc technologies CEO Amir Heshmatpour acquires $174,795 in stock By Investing.com - Investing.com UK
NeOnc Technologies (NTHI) CEO is buying more of his own stock - stocktitan.net
NeOnc Technologies (NTHI) CFO adds shares in open-market buy - stocktitan.net
NeOnc Technologies (NTHI) insider may sell $18,900 in stock - Stock Titan
Investor Determination to Beat Cancer Puts NeOnc’s Novel Therapies and Patented Platform in Focus - marketscreener.com
48.9% had no cancer progression at six months in NeOnc’s 24-person study - stocktitan.net
Neonc technologies CEO Amir Heshmatpour acquires $174,795 in stock - Investing.com
NeOnc Technologies Holdings CEO Buys More Shares After Promising Phase 2a NEO100 Data and Ahead of FDA Meeting - Quiver Quantitative
Insiders Continue Buying, as NeOnc Moves NEO100 Toward Its Next Regulatory Test - marketscreener.com
Neonc Technologies CEO Amir Heshmatpour buys $135,619 in shares By Investing.com - Investing.com Nigeria
Neonc Technologies CEO Amir Heshmatpour buys $135,619 in shares - Investing.com
NeOnc (NTHI) CEO now holds 3.13M shares after stock buy - Stock Titan
Neonc Technologies Holdings, Briacell Therapeutics and Oncolytics Biotech Have Report Clinical and Regulatory Developments Across Brain, Breast and Colorectal Cancer - marketscreener.com
Form 8K Neonc Technologies Holdings Inc For: 10 September By Investing.com - Investing.com Nigeria
NeOnc raises USD 15m to advance Phase II CNS cancer programs after NEO100 efficacy readout - AllSci
NeOnc Technologies Launches $15 Million Registered Direct Offering at $4.20 With Warrants - TradingView
NeOnc Technologies Company Profile & Introduction - Moomoo
NeOnc Technologies prices $15M registered direct offering By Investing.com - Investing.com Nigeria
NeOnc Technologies Holdings Secures $15 Million Registered Direct Offering After Positive Phase 2a Data and Insider Buying - Quiver Quantitative
NeOnc Raises $15 Million At Market Adding Fuel to the Strong NEO100 Data - marketscreener.com
Neonc Technologies Holdings Inc Stock (NTHI) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):